Hyperfine, Inc. (NASDAQ: HYPR - Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 1,250,028 shares, a growth of 46.4% from the December 31st total of 854,005 shares. Based on an average trading volume of 487,628 shares, the
GUILFORD, Conn.--(BUSINESS WIRE)--Strong evidence supports the use of AI-powered portable MRI for stroke detection in multiple clinical settings, including the emergency department.
GUILFORD, Conn.--(BUSINESS WIRE)--Results from the NEURO PMR study, presented by Dr. Laszlo Mechtler at the ASN Annual Meeting in San Juan, Puerto Rico, on January 16, 2026.
/PRNewswire/ -- The medical imaging world is hitting a massive reset button as AI-driven clinical intelligence transforms how we map the human heart. With the
GUILFORD, Conn.--(BUSINESS WIRE)--Prospective study is designed to evaluate the feasibility and visualization benefits of contrast-enhanced ultra-low-field portable MRI.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced preliminary, unaudited revenue, net cash burn, and cash and cash equivalents for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Preliminary, Unaudited Financial Results Preliminary, unaudited revenue for the fourth qua.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine announces the first analysis showing the AI-powered Swoop® portable MRI system reduces hospital costs and improves economics in acute care.
Hyperfine, Inc. (NASDAQ: HYPR - Get Free Report) saw a significant decline in short interest in December. As of December 15th, there was short interest totaling 659,270 shares, a decline of 15.6% from the November 30th total of 780,752 shares. Currently, 1.0% of the shares of the stock are sold short. Based on an average daily
GUILFORD, Conn.--(BUSINESS WIRE)--Swoop® portable MRI system receives CDSCO approval in India, expanding access to advanced brain imaging in a large, fast-growing healthcare market.
Hyperfine, Inc. (NASDAQ: HYPR - Get Free Report) dropped 6.8% during mid-day trading on Monday. The stock traded as low as $0.9250 and last traded at $0.9277. Approximately 3,219,550 shares changed hands during trading, an increase of 501% from the average daily volume of 536,113 shares. The stock had previously closed at $0.9959. Analyst Ratings
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine secures FDA clearance for new DWI sequence, significantly expanding the Swoop® system's clinical capabilities in acute neurological care.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine announces plans to present at the upcoming Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4th at 8:10 AM ET.
GUILFORD, Conn.--(BUSINESS WIRE)--$3.7M grant supports expanded use of portable MRI to evaluate brain development and guide targeted health interventions in underserved communities.
Hyperfine (NASDAQ: HYPR - Get Free Report) and Vasamed (OTCMKTS:VSMD - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk. Analyst Ratings This is a breakdown of recent recommendations for
Hyperfine, Inc. ( HYPR ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Webb Campbell Maria Sainz - CEO, President & Director Brett Hale - Chief Administrative Officer, CFO, Chief Compliance Officer, Treasurer & Corporate Secretary Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Presentation Operator Good afternoon, and welcome to Hyperfine's Third Quarter 2025 Earnings Conference Call.
Hyperfine, Inc. (HYPR) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.14 per share a year ago.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine today announced third quarter 2025 financial results and provided a business update.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine launches study to assess Swoop® System use in neurosurgical ORs, advancing accessible brain MRI across care settings.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine” or the “Company”) today announced it has priced its previously announced underwritten public offering of 14,000,000 shares of the Company's Class A common stock at a public offering price of $1.25 per share. All of the shares in the offering are being sold by Hyperfine. In addition, Hyperfine has granted the underwriter a 30-day option to purchase up to 2,100,000 shares of Class A common stock, which equals 15% of the.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine” or the “Company”) today announced that it has commenced an underwritten public offering of its Class A common stock or, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase Class A common stock. All securities to be sold in the offering will be sold by Hyperfine. In addition, Hyperfine intends to grant the underwriters a 30-day option to purchase up to 15% of the total number of securi.